Halozyme Therapeutics (HALO) Competitors $74.82 +1.48 (+2.02%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$74.79 -0.03 (-0.04%) As of 09/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, MDGL, EXAS, RGEN, and IONSShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences Repligen Ionis Pharmaceuticals Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Do analysts recommend HALO or BIIB? Halozyme Therapeutics currently has a consensus price target of $67.11, indicating a potential downside of 10.30%. Biogen has a consensus price target of $185.74, indicating a potential upside of 31.15%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 2 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.18Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 Which has more risk and volatility, HALO or BIIB? Halozyme Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Does the media prefer HALO or BIIB? In the previous week, Biogen had 25 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 43 mentions for Biogen and 18 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.10 beat Halozyme Therapeutics' score of 0.98 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 29 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in HALO or BIIB? 97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.9% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, HALO or BIIB? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$1.02B8.62$444.09M$4.3717.12Biogen$9.68B2.15$1.63B$10.4613.54 Is HALO or BIIB more profitable? Halozyme Therapeutics has a net margin of 47.28% compared to Biogen's net margin of 15.31%. Halozyme Therapeutics' return on equity of 150.85% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics47.28% 150.85% 29.19% Biogen 15.31%13.85%8.32% SummaryHalozyme Therapeutics and Biogen tied by winning 8 of the 16 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.56B$3.11B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio17.1221.1082.3726.60Price / Sales8.62368.84504.28161.15Price / Cash15.7243.5325.7028.92Price / Book26.358.1310.646.56Net Income$444.09M-$53.35M$3.28B$266.04M7 Day Performance2.76%0.73%0.10%-0.89%1 Month Performance24.72%7.76%8.91%4.34%1 Year Performance20.42%11.97%48.38%24.06% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.6455 of 5 stars$74.82+2.0%$67.11-10.3%+22.2%$8.56B$1.02B17.12390Insider TradeBIIBBiogen4.9069 of 5 stars$136.36-2.1%$185.74+36.2%-30.9%$20.42B$9.68B13.047,605Trending NewsINCYIncyte4.6484 of 5 stars$84.76-0.3%$81.60-3.7%+31.1%$16.61B$4.24B19.262,617Positive NewsShort Interest ↑UTHRUnited Therapeutics4.3805 of 5 stars$305.38-2.2%$382.00+25.1%+11.1%$14.08B$2.88B11.921,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑NBIXNeurocrine Biosciences4.8295 of 5 stars$133.99-1.1%$159.50+19.0%+8.8%$13.43B$2.36B39.641,800Positive NewsShort Interest ↑BMRNBioMarin Pharmaceutical4.9913 of 5 stars$58.50-0.1%$93.17+59.3%-35.6%$11.25B$2.85B17.363,040Positive NewsAnalyst ForecastEXELExelixis4.8111 of 5 stars$37.90-1.9%$44.06+16.2%+43.1%$10.40B$2.17B18.221,147Analyst RevisionMDGLMadrigal Pharmaceuticals4.1446 of 5 stars$412.23-0.6%$445.71+8.1%+84.1%$9.21B$180.13M-32.0890EXASExact Sciences4.7959 of 5 stars$45.66-3.8%$67.43+47.7%-17.9%$8.99B$2.76B-8.417,000Positive NewsShort Interest ↑RGENRepligen4.8223 of 5 stars$121.26-2.8%$169.45+39.7%-18.1%$7.02B$634.44M-485.021,778News CoveragePositive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.2065 of 5 stars$41.82-2.0%$60.92+45.7%+27.9%$6.80B$705M-22.731,069Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors BMRN Competitors EXEL Competitors MDGL Competitors EXAS Competitors RGEN Competitors IONS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HALO Stock Alerts